# Georgia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Georgia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Georgia (GEO)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $10.5M
- Products: 24
- Buyer markets: 24
- Average CAGR: +21.8%
- Global sector size: $608.2B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $290.3B | $867.5K | $110.3B | +21.2% | 19 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $131.3B | $265.5K | $52.5B | +38.9% | 9 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $26.7B | $50.6K | $30.8B | +119.0% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.0B | $1.4M | $19.0B | +12.1% | 11 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $30.4B | $319.2K | $16.7B | +28.6% | 7 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $20.4B | $3.3M | $8.8B | +40.3% | 5 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $8.3B | $5.8K | $8.5B | +5.8% | 1 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $12.8B | $60.8K | $8.3B | +4.6% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $18.7B | $319.0K | $8.3B | +18.6% | 5 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $8.5B | $455.8K | $5.0B | +65.8% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $5.2B | $40.1 | $3.2B | -29.3% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.0B | $305.3 | $2.9B | +3.0% | 2 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $3.2B | $2.5K | $2.6B | -51.2% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.0B | $5.8K | $2.0B | -11.0% | 1 | +0.0% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $390.2K | $1.9B | +25.6% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $3.6B | $9.4K | $1.8B | +43.4% | 2 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $129.1 | $1.8B | -24.9% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $37.7 | $1.4B | -32.3% | 1 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $875.7M | $2.1K | $1.3B | +4.2% | 1 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $1.1B | $1.6K | $1.1B | -22.6% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $481.2 | $981.0M | -4.1% | 1 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $1.4B | $3.0M | $891.3M | +1.2% | 1 | +0.2% |
| HS 300449 - Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $12.5K | $841.5M | +5.6% | 1 | +0.0% |
| HS 330290 - Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $1.3B | $1.5K | $803.3M | +0.5% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $97.7B calculated opportunity across 13 products.
- Switzerland, Liechtenstein (CHE): $33.9B calculated opportunity across 3 products.
- Germany (DEU): $28.8B calculated opportunity across 11 products.
- Netherlands (NLD): $16.4B calculated opportunity across 4 products.
- China (CHN): $14.7B calculated opportunity across 5 products.
- Canada (CAN): $12.7B calculated opportunity across 7 products.
- Belgium (BEL): $11.4B calculated opportunity across 2 products.
- France (FRA): $9.8B calculated opportunity across 6 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- United Kingdom (GBR): $9.6B calculated opportunity across 5 products.
- Spain (ESP): $8.6B calculated opportunity across 4 products.
- Ireland (IRL): $5.8B calculated opportunity across 3 products.

## Growth stars

- HS 300214: +119.0% average CAGR, $30.8B calculated opportunity.
- HS 330300: +65.8% average CAGR, $5.0B calculated opportunity.
- HS 300290: +43.4% average CAGR, $1.8B calculated opportunity.
- HS 330499: +40.3% average CAGR, $8.8B calculated opportunity.
- HS 300215: +38.9% average CAGR, $52.5B calculated opportunity.
- HS 300212: +28.6% average CAGR, $16.7B calculated opportunity.
- HS 284590: +25.6% average CAGR, $1.9B calculated opportunity.
- HS 300490: +21.2% average CAGR, $110.3B calculated opportunity.
- HS 382200: +18.6% average CAGR, $8.3B calculated opportunity.
- HS 382499: +12.1% average CAGR, $19.0B calculated opportunity.

## Diversification opportunities

- HS 300490: 19 buyer markets, $110.3B calculated opportunity.
- HS 382499: 11 buyer markets, $19.0B calculated opportunity.
- HS 300215: 9 buyer markets, $52.5B calculated opportunity.
- HS 300212: 7 buyer markets, $16.7B calculated opportunity.
- HS 330499: 5 buyer markets, $8.8B calculated opportunity.
- HS 382200: 5 buyer markets, $8.3B calculated opportunity.
- HS 300214: 3 buyer markets, $30.8B calculated opportunity.
- HS 293499: 3 buyer markets, $8.3B calculated opportunity.
- HS 330300: 3 buyer markets, $5.0B calculated opportunity.
- HS 300439: 2 buyer markets, $3.2B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.